Strategic partnership Enzyre BV and Takeda for better diagnostics for bleeding disorders
Takeda announced to have entered into a strategic partnership with Enzyre BV, a Radboudumc spin-off company. The partnership aims to accelerate the development of a diagnostic technology platform that improves the standard of care for patients with bleeding disorders.
Enzyre was founded in 2016 with the mission to save patients from bleeding to death with their Enzypad technology. Their vision is to create a point of care diagnostic platform that will measure a multitude of enzymatic reactions based on chemiluminescence.
Read the Takeda announcement here: https://lnkd.in/dJSqpRk
Related news items
New start-up Patholyt will bring AI research into pathology diagnostics21 September 2021
Patholyt is on a mission to accelerate the adoption of artificial intelligence in pathology diagnostics and improve the chances of cancer patients worldwide. Patholyt is a spin-off from Radboudumc, a frontrunner in computational pathology research.read more
Radboudumc enhances Luchtbrug in collaboration with FindAir17 August 2021
Luchtbrug is a platform for online asthma care for children and young people, which (partly) replaces outpatient visits.read more
ScreenPoint Medical raises $28 million for further development Series C funding led by Insight Partners2 August 2021
ScreenPoint Medical has raised $28 million in a Series C financing. ScreenPoint Medical is a spin-off of the Radboudumc.read more
Radboudumc and SyncVR Medical looking to boost the use of virtual reality in healthcare15 July 2021
Aiming to provide better care with the help of virtual reality applications, Radboudumc is going to collaborate intensively with startup SyncVR Medical. To this end, the two partners signed a two-year collaboration agreement.read more
Teaming up to develop an effective cure for mycobacterium abscessus disease using inhaled tigecycline7 July 2021
PureIMS, Radboudumc, and Sever Pharma Solutions are now teaming up to develop an effective cure for this chronic and debilitating disease.read more